小鼠肝损伤模型的建立及HSS对肝的保护作用的初探

从三周龄幼鼠制备了肝细胞再生刺激物质（Ｈｅｐａｔｉｃｒｅｇｅｎｅｒａｔｉｏｎｓｔｉｍｕｌａｔｉｎｇｓｕｂｓｔａｃｅ，ＨＳＳ）研究结果提示：注射ＣＣｌ４导致小鼠血清ＡＬＴ显著升高，ＡＳＴ也明显增高，表明ＣＣｌ４致小鼠急性肝损伤，而ＨＳＳ对肝损伤具有显著保护作用，为深入研究ＨＳＳ对肝保护作用机理、ＨＳＳ用于临床的可行性提供了基础。     

Sputum induction as a research tool for the study of human respiratory mucus

The study objectives were to compare in vitro transportability and physical properties of respiratory mucus, obtained invasively by direct collection (DC) right after endotracheal intubation and non-invasively by sputum induction with 3% hypertonic saline solution inhalation (SI) 24 h before the anesthesia. Twenty-two patients with no pulmonary disease scheduled for elective abdominal surgical procedures were studied. The parameters analyzed and the main results are as follows. (1) Transportability by cilia (MCT), SI was higher than DC (0.94+/-0.25 and 0.62+/-0.25; P<0.001). There was a significant correlation between the two methods and DC could be estimated by: DC=0.21+(0.44 SI) (r=0.44; P<0.001). (2) Transportability by cough (CC), SI was higher than DC (68.23+/-32.1 and 33.58+/-19.04 mm; P=0.002). (3) Contact angle (CA), SI was lower than DC (10+/-3 degrees and 22+/-14 degrees ; P=0.025). (4) Rheological properties (no significant difference obtained between SI and DC). These results indicated that SI changes mucus physical properties and transportability in non-expectorators.     

肝细胞再生刺激物质长期使用对慢性肝损害肝细胞倍体影响的实验研究

采用新生小牛(未进食前)肝研制的肝细胞再生刺激物质(HSS),对CCL_4造成慢性肝损伤进行长期治疗.利用同位素~3H=TdR掺入和流式细胞计数分析相结合的方法,探讨HSS长期使用有无致畸作用.结果表明,①Hss在体外、内均能刺激肝细胞DNA合成,其Cpm值低于急性肝损伤增生值;②肝细胞合成周期以Go/1期为主;③增生的肝细胞DNA倍体为4,8倍体等整倍体细胞为主,未见异常非整倍体细胞.我们结论是利用新生小牛肝中制备的HSS长期使用无致畸,致癌”作用.     

用肝细胞生长因子治疗25例重症肝炎的临床观察

本文用肝细胞生长因子（HSS）加综合治疗方法对25例重症肝炎患者进行了治疗，并对20例重症肝炎病人仅用综合疗法进行对照观察。结果提示：经2个疗程治疗后，治疗组血清转氨酶，胆红素及凝血酶原时间好转例数及恢复正常例数均明显高于对照组（P＜0．05）。但在两个疗程时间内，其白，球蛋白比例改善例数在二组间未见有差异（P＞0．05）。对照分析还显示，治疗组病人的总体治疗有效率（100％）明显高于对照组（45％）（P＜0．05）。提示肝细胞生长因子治疗重症肝炎病人有较好疗效，是一种较好的治疗药物。     

“环太平洋－2016”军演特混编队医疗后送的组织实施与启示

中国海军“和平方舟”号医院船于2016年6月15日从浙江舟山启航,赴夏威夷参加“环太平洋－2016”联合军演。该文总结了此次环太军演卫勤保障中特混编队医疗后送的组织实施方法及对我军的启示,为我军后续组织大规模联合军演提供参考。     

The Hospital for the Ruptured and Crippled: William Bradley Coley, Third Surgeon-in-Chief 1925–1933

In January 1925, the Board of Managers of the New York Society for the Relief of the Ruptured and Crippled appointed William Bradley Coley, M.D., age 63, Surgeon-in-Chief of the Hospital for the Ruptured and Crippled (R & C) to succeed Virgil P. Gibney who submitted his resignation the month before. It would be the first time a general surgeon held that position at the oldest orthopedic hospital in the nation, now known as Hospital for Special Surgery (HSS). Coley had been on staff for 36 years and was world famous for introducing use of toxins to treat malignant tumors, particularly sarcomas. A graduate of Yale College and Harvard Medical College, Coley interned at New York Hospital and was appointed, soon after, to the staff of the New York Cancer Hospital (now Memorial Sloan Kettering Cancer Center) located at that time at 106th Street on the West Side of New York. With his mentor Dr. William Bull, Coley perfected the surgical treatment of hernias at R & C. He was instrumental in raising funds for his alma maters, Yale, Harvard and Memorial Hospital. His crusade in immunology as a method of treatment for malignant tumors later fell out of acceptance in the medical establishment. After his death in 1936, an attempt to revive interest in use of immunotherapy for inoperable malignancies was carried out by his daughter, Helen Coley Nauts, who pursued this objective until her death at age 93 in 2000. Coley's health deteriorated in his later years, and in 1933, he resigned as chief of Bone Tumors at Memorial Hospital and Surgeon-in-Chief at R & C, being succeeded at Ruptured and Crippled as Surgeon-in-Chief by Dr. Eugene H. Pool. William Bradley Coley died of intestinal infarction in 1936 and was buried in Sharon, Connecticut.     

浅析关节镜辅助下经皮内固定和切开复位内固定治疗胫骨平台骨折的应用价值

目的 对关节镜辅助下经皮内固定和切开复位内固定治疗胫骨平台骨折的临床应用价值进行对比分析.方法 对180例胫骨平台骨折患者进行前瞻性的研究,其中胫骨平台Ⅱ型骨折(A组)112例、Ⅲ型骨折(B组)68例.A组和B组分别按入院日期的单双号随机分为A1组、A2组和B1组、B2组.A1组(56例)和B1组(34例)均采取切开复位内固定治疗,A2组(56例)和B2组(34例)均采取关节镜辅助下经皮内固定治疗.将同一类型胫骨平台骨折不同治疗方法下的患者术后功能恢复情况进行评估比较.结果 A组:A1组优12例,良26例,可12例,差6例,优良率为67.9％(38/56);A2组优19例,良34例,可3例,差0例,优良率为94.6％(53/56).两组优良率比较差异有统计学意义(P＜0.01).A1组和A2组术后膝关节HSS评分及膝关节屈伸活动度比较差异有统计学意义[(73.21±8.32)分比(85.58±9.89)分、(35.6±6.6).比(55.1±8.8).](P＜0.01).B组:B1组优8例,良16例,可7例,差3例,优良率为70.6％(24/34);B2组优12例,良21例,可1例,差0例,优良率为97.1％(33/34).两组优良率比较差异有统计学意义(P＜0.01).B1组和B2组术后膝关节HSS评分及膝关节屈伸活动度比较差异有统计学意义[(75.32±7.99)分比(86.41±10.21)分、(33.9±7.2).比(56.6±10.5).](P＜0.01).结论 关节镜辅助下经皮内固定方法无论治疗Ⅱ型还是Ⅲ型胫骨平台骨折,其疗效都要优于切开复位内固定方法,而且该方法为微创疗法,值得在临床中加以推广应用.     

肝细胞生长刺激因子的实验研究

将人胎肝肝细胞生长刺激因子(HSS)用于硫代乙酰胺(TAA)引起急性肝中毒的小白鼠,通过观察SGPT及肝脏组织学的变化来评价HSS的治疗作用。预先使用HSS能减轻TAA对肝细胞的损害。预防组与对照组的SGPT水平有显著性差异(P〈0.01),肝细胞的变性坏死程度亦较轻。将HSS用于TAA中毒小鼠能很快地降低SGPT,与对照组比较有明显差异(P〈0.01)。同时可见肝细胞变性坏死程度逐渐减轻,肝细胞增生象逐日增多。实验结果表明,人胎肝HSS具有保护肝细胞及促进肝细胞增生的作用。     

Electroacupuncture for Reflex Sympathetic Dystrophy after Stroke: A Meta-Analysis

Background: Reflex sympathetic dystrophy (RSD) is the common complication among stroke and cerebral injury patients, which is lack of safe and effective treatment. Electroacupuncture (EA) may potentially be a reliably therapy, but the evidence is insufficiency. Methods: Cochrane Library, MEDLINE, Embase, Chinese National Knowledge Infrastructure, Wan Fang Data, the Chinese Biology Medicine disc, etc., were searched, until July 20, 2018. We included random control trials that contrast EA with conventional rehabilitation therapy for the treatment of RSD. Main outcomes were visual analog scale score and Fugl-Meyer upper limb motor function scoring scale, other outcomes such as Barthel index, and hand swelling score were also collected. Data in included studies were extracted into an excel and pooled by Stata/MP 14.1. Results: We incorporated 13 studies involving 1040 RSD patients and outcomes were from 2 to 6 weeks' follow-up. The analgesic effect between 2 groups had statistically significant difference (weighted mean difference [WMD] = ?1.122, 95% confidence interval [CI] [?1.682 to ?.562], P?=?.000], a statistical difference existed in improving dysfunction between 2 groups: (WMD?=?6.039, 95% CI [2.231?.916], P?=?.000). EA groups had a better effect on improving activities of daily life abilities (WMD?=?12.170, 95% CI [6.657?17.682], P < .00011] and better detumescence effect (WMD = ?.800, 95% CI [?1.972 to ?.212], P = .000] contrast to conventional rehabilitation therapy. Conclusions: This meta-analysis supports that EA has a positive effect on alleviating pain, improving limb dysfunction, and promoting activities of daily living. On account of moderate-quality random control trials and high heterogeneity, further high-quality studies are imperative to optimize the EA treatment program.